home / stock / ntra / ntra quote
Last: | $92.67 |
---|---|
Change Percent: | 4.58% |
Open: | $89.44 |
Close: | $88.61 |
High: | $92.74 |
Low: | $89.44 |
Volume: | 527,949 |
Last Trade Date Time: | 04/23/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$92.67 | $89.44 | $88.61 | $92.74 | $89.44 | 527,949 | 04-23-2024 |
$88.61 | $86.46 | $88.61 | $89.28 | $85.095 | 1,120,760 | 04-22-2024 |
$85.28 | $87.01 | $85.28 | $87.195 | $83.13 | 2,526,074 | 04-19-2024 |
$87.28 | $89.64 | $87.28 | $90.33 | $87.19 | 1,172,503 | 04-18-2024 |
$90.33 | $91.06 | $90.33 | $91.06 | $89.06 | 694,057 | 04-17-2024 |
$90.32 | $90.71 | $90.32 | $91.495 | $89.72 | 1,389,481 | 04-16-2024 |
$90.42 | $94.3 | $90.42 | $94.6 | $90.125 | 1,182,121 | 04-15-2024 |
$94.47 | $96.68 | $94.47 | $97.16 | $93.82 | 959,947 | 04-12-2024 |
$96.71 | $96.13 | $96.71 | $96.77 | $94.94 | 1,060,899 | 04-11-2024 |
$96.5 | $94.73 | $96.5 | $97.98 | $92.81 | 1,041,490 | 04-10-2024 |
$97.48 | $95.65 | $97.48 | $97.6 | $95.15 | 1,197,459 | 04-09-2024 |
$95.43 | $97.64 | $95.43 | $97.895 | $94.75 | 1,265,259 | 04-08-2024 |
$96.75 | $94.62 | $96.75 | $98.82 | $94.43 | 1,541,036 | 04-05-2024 |
$92.36 | $92.71 | $92.36 | $96.8 | $92.13 | 1,977,348 | 04-04-2024 |
$92.61 | $91.29 | $92.61 | $93.92 | $91.09 | 1,282,273 | 04-03-2024 |
$91.91 | $91.85 | $91.91 | $92.85 | $89.95 | 972,646 | 04-02-2024 |
$92.96 | $90.91 | $92.96 | $93.5 | $89.52 | 1,092,697 | 04-01-2024 |
$91.46 | $90.13 | $91.46 | $92.42 | $89.2 | 971,264 | 03-29-2024 |
$91.46 | $90.13 | $91.46 | $92.42 | $89.2 | 971,264 | 03-28-2024 |
$90.46 | $90.4 | $90.46 | $90.855 | $87.89 | 1,617,256 | 03-27-2024 |
News, Short Squeeze, Breakout and More Instantly...
Demonstrates commitment to generating real-world clinical evidence to change disease management and improve patient outcomes Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the...
ProActive study shows Natera’s Prospera Kidney™ test detects rejection five months before biopsy Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting ...
Prospective, multi-center Trifecta-Heart and DTRT-2 studies demonstrate excellent performance of the Prospera Heart test for detecting rejection in adults and pediatrics Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of...